Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression -196% Improvement Relative Risk Hospitalization 52% Case 14% Case (b) 6% Tirupakuzhi Vijayaraghavan et al. CTRI/2020/05/025067 HOPE HCQ RCT PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? RCT 414 patients in India (June 2020 - February 2021) Trial underpowered to detect differences Tirupakuzhi Vijayaraghavan et al., BMJ Open, doi:10.1136/bmjopen-2021-059540 Favors HCQ Favors control
Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-confirmed COVID-19 infections among healthcare workers: a multicentre, parallel-group randomised controlled trial from India
Tirupakuzhi Vijayaraghavan et al., BMJ Open, doi:10.1136/bmjopen-2021-059540, HOPE, CTRI/2020/05/025067
Tirupakuzhi Vijayaraghavan et al., Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the.., BMJ Open, doi:10.1136/bmjopen-2021-059540, HOPE, CTRI/2020/05/025067
Jun 2022   Source   PDF  
  All Studies   Meta
Low-dose prophylaxis RCT with low-risk healthcare workers in India, showing no significant differences. Symptomatic case results are not provided. Followup was over 6 months, however treatment ended after 3 months. 21% of patients discontinued treatment before 3 months (Table S2).
risk of progression, 196.2% higher, RR 2.96, p = 1.00, treatment 1 of 211 (0.5%), control 0 of 203 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), ICU/HDU.
risk of hospitalization, 51.9% lower, RR 0.48, p = 0.62, treatment 1 of 211 (0.5%), control 2 of 203 (1.0%), NNT 196.
risk of case, 14.2% lower, RR 0.86, p = 0.73, treatment 11 of 211 (5.2%), control 12 of 203 (5.9%), NNT 143, adjusted per study, odds ratio converted to relative risk, confirmed cases, multivariable.
risk of case, 5.7% lower, RR 0.94, p = 0.90, treatment 12 of 211 (5.7%), control 12 of 203 (5.9%), NNT 446, adjusted per study, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tirupakuzhi Vijayaraghavan et al., 1 Jun 2022, Randomized Controlled Trial, India, peer-reviewed, mean age 32.1, 21 authors, study period 29 June, 2020 - 4 February, 2021, trial CTRI/2020/05/025067 (HOPE).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Open access Original research To cite: Tirupakuzhi Vijayaraghavan BK, Jha V, Rajbhandari D, et al. Hydroxychloroquine plus personal protective equipment versus personal protective equipment alone for the prevention of laboratory-­ confirmed COVID-­19 infections among healthcare workers: a multicentre, parallel-­group randomised controlled trial from India. BMJ Open 2022;12:e059540. doi:10.1136/ bmjopen-2021-059540 ► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (​ bmjopen-2021-059540). Received 24 November 2021 Accepted 13 May 2022 © Author(s) (or their employer(s)) 2022. Re-­use permitted under CC BY-­NC. No commercial re-­use. See rights and permissions. Published by BMJ. For numbered affiliations see end of article. Correspondence to Dr Bharath Kumar Tirupakuzhi Vijayaraghavan; ​bharathkumartv@​gmail.c​ om Bharath Kumar Tirupakuzhi Vijayaraghavan ‍ ‍,1,2 Vivekanand Jha,2 Dorrilyn Rajbhandari,3 Sheila Nainan Myatra,4,5 Arpita Ghosh ‍ ‍,2 Amritendu Bhattacharya,2 Sumaiya Arfin,2 Abhinav Bassi,2 Lachlan Hugh Donaldson,3 Naomi E Hammond ‍ ‍,6 Oommen John,2 Rohina Joshi,7 Mallikarjuna Kunigari,2 Cynthia Amrutha,8 Syed Haider Mehdi Husaini,9 Subir Ghosh,10 Santosh Kumar Nag,11 Hari Krishnan Selvaraj,12 Viny Kantroo,13 Kamal D Shah,14 Balasubramanian Venkatesh,3,15,16 for the HOPE Investigators ABSTRACT Objectives To determine whether hydroxychloroquine when used with personal protective equipment reduces the proportion of laboratory-­confirmed COVID-­19 among healthcare workers in comparison to the use of personal protective equipment alone. Design Multicentre, parallel-­group, open-­label randomised trial. Enrolment started on 29 June 2020 and stopped on 4 February 2021. Participants randomised in HydrOxychloroquine Prophylaxis Evaluation were followed for 6 months. Setting 9 hospitals across India. Participants Healthcare workers in an environment with exposure to COVID-­19 were randomised in a 1:1 ratio to hydroxychloroquine plus use of personal protective equipment or personal protective equipment alone. 886 participants were screened and 416 randomised (213 hydroxychloroquine arm and 203 personal protective equipment). Intervention Participants in intervention arm received 800 mg of hydroxychloroquine on day of randomisation and then 400 mg once a week for 12 weeks in addition to the use of personal protective equipment. In the control arm, participants continued to use personal protective equipment alone. Main outcome Proportion of laboratory-­confirmed COVID-­19 in the 6 months after randomisation. Results Participants were young (mean age 32.1 years, SD 9.1 years) with low-­comorbid burden. 47.4% were female. In the 6 months after randomisation (primary analysis population=413), 11 participants assigned to the hydroxychloroquine group and 12 participants assigned to the standard practice group met the primary STRENGTHS AND LIMITATIONS OF THIS STUDY ⇒ Our trial is the largest multicentre trial evaluating hydroxychloroquine prophylaxis for COVID-­19 from a low and middle-­income country setting. ⇒ The trial tested the dose of hydroxychloroquine recommended by the Indian regulatory agencies and had the longest follow-­up duration among hydroxychloroquine trials. ⇒ Our trial included a diverse set of participants, both in terms of balance of men and women, but also in terms of the various healthcare..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop